The Latest

NOW AVAILABLE: For the European Psoriasis Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q4, 2016.

Humira kept its status as promotions leader during Q4, producing 29% of the total promotional volume. Enbrel promoted its status as a biologic approved for PsO pediatric patients, while Humira featured its new enhanced presentation. The brands focused on patient convenience, new approvals, new clinical studies, and patient services, while biosimilars maintained comparability and cost-savings as main promotional messages. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

2016-Q4-Psoriasis

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the Canadian and European MS Markets – A SnapShot analysis of promotional messaging and DTC initiatives for Q3, 2016.

Overall, 62 new pieces were distributed for the Canadian and European MS markets, a slight decrease from last quarter. Gilenya captured the highest volume with 24% of promotional materials in Q3, replacing Tysabri as the promotions leader. The main topics were new patient support programs (e.g. CoPACT), efficacy based on real-life clinical studies (e.g. ATTAIN), and the introduction of a new therapy, Zinbryta. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Ex-US-Q3-2016-MS

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European Hepatitis C Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2016.

AbbVie maintained its lead in terms of the proportion of the promotional volume received, with Exviera/Viekirax materials distributed in all countries analyzed. Epclusa’s July approval was announced in Germany alongside an expected availability date of July 18, 2016, while in the UK, Janssen stated that it would not renew Incivo’s license when marketing authorizations ceased in September 2016. Clinical trial data continued to be a focus across brands, while an increase was observed in DTC materials, most of which were unbranded patient newsletters. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Ex-US-Q3-2016-Hep-C

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the Diabetes Insulin Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2016.

There were 143 new pieces received in Q3, 2016. Education and support program messages were the most frequently observed for most of the brands. Sanofi’s Toujeo was the promotional volume leader, comprising 43% of the market, and advertised a free education session from Certified Diabetes Educators for patients. Lilly’s Humalog franchise introduced healthcare professionals to the website www.Humalogavailability.com, which helps them determine if Humalog is covered in their patients’ insurance coverage. NovoNordisk informed healthcare professionals that Levemir is still offered in a vial and encouraged pediatric endocrinologists to prescribe Levemir FlexTouch. NovoNordisk also encouraged healthcare professionals to check out new features added to the NovoMedLink website. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Diabetes-Insulin

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the Hepatitis C Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2016.

Gilead’s Epclusa, Harvoni, and Sovaldi comprised an overwhelming portion of marketing materials, most of which, were campaigns designed to promote these products as part of Gilead’s robust Hep-C franchise. Gilead added to the relatively new “Expand What’s Possible” campaign by refreshing the imagery featured within the campaign.  Several of the Q3 marketing materials co-promoted Epclusa and Harvoni within a single document and featured the headline “A cure for every type.” Patient assistance was also a component of the messaging, with references to “The Onward program” which offers potential and current Epclusa or Harvoni patients guidance to help them on their treatment path. Abbvie’s initial launch promotions for Viekira XR began circulating during the third quarter, which blended digital promotion along with announcements of the product’s recent FDA approval. Merck announced the FDA approval of Zepatier for the treatment of chronic hepatitis C genotype 1 or 4 in adults, incorporating positioning of the brand with main messages supporting the headline “Powerful Cure” and weaving in campaign content that shared the patient “Story” with targeted HCPs. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Q3-2016-Hepatitis-C

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the European NSCLC Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q3, 2016.

The European NSCLC market produced 50 pieces during Q3 and its promotional distribution was dominated by Nivolumab BMS/Opdivo, which single handedly acquired 34% of the market’s total volume. Nivolumab BMS continued its transition to Opdivo with pieces from France, Germany, Italy, and the UK, featuring the new trade name. In addition, Portrazza introduced a new campaign theme with the “Mosaic Lungs” imagery. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Ex-US-2016-Q3-NSCLC

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the European PCSK9 Inhibitors Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q3, 2016.

The volume of promotional pieces decreased during Q3 compared to the one generated in the previous quarter. Repatha became the promotional leader during this quarter by capturing 56% of promotional volume in the European PCSK9 inhibitors market. Praluent and Repatha emphasized their efforts through clinical studies to support efficacy, safety, and the role of PCKS9 inhibitors in the treatment of CV risk patients. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Ex-US-2016-Q3-PSCK9-inhibit

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Prostate Cancer Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2016.

During the third quarter, Janssen Biotech’s Zytiga held the largest promotional volume with 29% of the prostate cancer market, closely followed by Xtandi and Firmagon. A new variation of Zytiga’s “Let’s Do This” campaign was geared toward treating elderly patients. Astellas Pharma premiered Xtandi’s “Start Button” campaign with the headline “Upon progression on GnRH therapy, start Xtandi to extend survival.” Abbvie’s Lupron Depot was promoted as the “#1 prescribed GnRHa in the US since 1989.” Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Q3-2016-Prostate-Cancer

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the European Psoriatic Arthritis Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q3, 2016.

The volume of promotional materials produced during this quarter was similar from that of Q2. Humira maintained its promotional leadership by capturing 18% of the generated material for PsA in Europe. Clinical studies played an important role promoting efficacy and safety in PsA in most brands, while Remsima explained the variability of the originally approved molecule in all biologics and biosimilars. Proper waste management was introduced as well as new campaign imagery. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Ex-US-2016-Q3-PsA

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the Non-Hodgkin Lymphoma Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q3 2016.

Overall, Teva’s Bendeka and Gilead’s Zydelig both captured the largest promotional volume with 31% of the NHL market. Bendeka significantly utilized email promotions, while advertising convenient product features, such as short-time infusion, and Teva’s CORE Program, which assisted patients and healthcare providers with the reimbursement process. Zydelig’s “B-cell” campaign continued to promote a first-in-class mechanism of action and powerful efficacy in treating patients with relapsed follicular lymphoma. The product’s only DTC promotion focused on resources offered through Access Connect. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

q3-2016-nhl

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com